Table 3.
Outcome | Arm A: Daratumumab (n=15) |
Arm B: Edicotinib (n=10) |
TOX | ||
Patients with any TOX event | 2 (13%) | 2 (20%) |
Surgery delay | 0 (0%) | 0 (0%) |
Surgical complications | 0 (0%) | 1 (10%) |
Grade 3 infusion reactions >6 hours | 0 (0%) | NA |
Related grade 2 lasting >14 days | 1 (7%)—infection | 1 (10%)—lymphocyte count decrease |
Related grade 3, not excepted | 1 (7%)—urticaria | 0 (0%) |
pCR | ||
pCR empirical estimate N (%) | 0 (0%) | 0 (0%) |
pCR, pathologic complete remission.